Adverse events and clinical courses of the patients who underwent TCR-T cell transfer
| Patient . | Therapy-related adverse event . | Hematological effect . | WT1-mRNA level in PB on day 58 (day 0) (copy/mgRNA) . | Therapies after TCR-T cell transfer . |
|---|---|---|---|---|
| TCR-WT-02-M01 | Skin reaction (G1)* | Decrease of abnormal erythroblasts in PB | 5800 (2700) | Allogeneic HSCT |
| TCR-WT-03-M02 | None | Progressive disease | 29 000 (8400) | None |
| TCR-WT-06-E03 | Skin reaction (G1)* | Decrease of blasts in BM | 4300 (2000) | Cytarabine/aclarubicin |
| TCR-WT-07-M03 | Skin reaction*(G1), facial edema (G1), dermatitis (G1) | Progressive disease | 3600 (930) | Azacitidine |
| TCR-WT-08-N04 | Fever (G1), skin reaction (G1)* | Progressive disease | 76 000 (70 000) | Cytarabine/aclarubicin/G-CSF, lenalidomide, hydroxyurea |
| TCR-WT-09-N05 | Phlebitis (G2), arrhythmia (G1), skin reaction (G1)*, stomatitis (G1) | Progressive disease | 45 000 (17 000) | Hydroxyurea, cytarabine |
| TCR-WT-10-F02 | Skin reaction (G1)* | Stable disease | 17 000 (17 000) | None |
| TCR-WT-11-E04 | Skin reaction (G1)* | Decrease of blasts in BM | 6300 (6600) | None |
| Patient . | Therapy-related adverse event . | Hematological effect . | WT1-mRNA level in PB on day 58 (day 0) (copy/mgRNA) . | Therapies after TCR-T cell transfer . |
|---|---|---|---|---|
| TCR-WT-02-M01 | Skin reaction (G1)* | Decrease of abnormal erythroblasts in PB | 5800 (2700) | Allogeneic HSCT |
| TCR-WT-03-M02 | None | Progressive disease | 29 000 (8400) | None |
| TCR-WT-06-E03 | Skin reaction (G1)* | Decrease of blasts in BM | 4300 (2000) | Cytarabine/aclarubicin |
| TCR-WT-07-M03 | Skin reaction*(G1), facial edema (G1), dermatitis (G1) | Progressive disease | 3600 (930) | Azacitidine |
| TCR-WT-08-N04 | Fever (G1), skin reaction (G1)* | Progressive disease | 76 000 (70 000) | Cytarabine/aclarubicin/G-CSF, lenalidomide, hydroxyurea |
| TCR-WT-09-N05 | Phlebitis (G2), arrhythmia (G1), skin reaction (G1)*, stomatitis (G1) | Progressive disease | 45 000 (17 000) | Hydroxyurea, cytarabine |
| TCR-WT-10-F02 | Skin reaction (G1)* | Stable disease | 17 000 (17 000) | None |
| TCR-WT-11-E04 | Skin reaction (G1)* | Decrease of blasts in BM | 6300 (6600) | None |
PB, peripheral blood.
Reactions at peptide injection sites.